Stock ticker :
NYSE
PFE
AS OF
Jan 19, closing price
Price
$53.54
Change
-$0.59 (-1.09%)
Capitalization
$300.5b
PFE
Stock ticker :
NYSE
19 days until earnings call
Intraday data for
Jan 19, closing price
Price
$53.54
Change
-$0.59 (-1.09%)
Capitalization
$300.5b

(PFE) Stock Forecast and AI Recommendations

a manufacturer of vaccines and injectable biologic medicines
Industry PharmaceuticalsMajor

Pfizer (PFE) Stock Stock Prediciton and Price Targets

Stock market charts, price targets, analyst ratings and a financial calendar
a manufacturer of vaccines and injectable biologic medicines
Industry PharmaceuticalsMajor
A.I.dvisor published
a Summary for PFE with price predictions.
4:00 PM EST Jan 19

PFE's RSI Oscillator peaks and leaves overbought zone

The 10-day RSI Indicator for PFE moved out of overbought territory on December 21, 2021. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 43 instances where the indicator moved out of the overbought zone. In 21 of the 43 cases the stock moved lower in the days that followed. This puts the odds of a move down at 49%.

Stock Forecast, Price, News, Quote

Current price $53.54 crossed the support line at $54.24 and is trading between $54.24 support and $43.69 support lines. Throughout the month of 12/16/21 - 01/19/22, the price experienced a -13% Downtrend. During the week of 01/11/22 - 01/19/22, the stock fell -6%.

Technical Analysis (Indicators)
Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on December 30, 2021. You may want to consider selling the stock, shorting the stock, or exploring put options on PFE as a result. In 40 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 47%.

The Moving Average Convergence Divergence Histogram (MACD) for PFE turned negative on December 28, 2021. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 20 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 45%.

PFE moved below its 50-day Moving Average on January 18, 2022 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PFE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 43%.

Bullish Trend Analysis

The Stochastic Indicator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a +1.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where PFE advanced for three days, in 161 of 314 cases, the price rose further within the following month. The odds of a continued upward trend are 51%.

PFE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 130 of 325 cases where PFE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 40%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 74 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 74 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. PFE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 12 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 62, placing this stock better than average.

The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.970) is normal, around the industry mean (4.977). P/E Ratio (15.552) is within average values for comparable stocks, (29.340). Projected Growth (PEG Ratio) (1.270) is also within normal values, averaging (2.436). Dividend Yield (0.029) settles around the average of (0.025) among similar stocks. P/S Ratio (4.388) is also within normal values, averaging (4.445).

A.I.dvisor published
Pfizer Earnings Data

PFE is expected to report earnings to fall 34.93% to 87 cents per share on February 08

Pfizer PFE Stock Earnings Report
Q4'21
Est.
$0.87
Q3'21
Beat
by $0.26
Q2'21
Beat
by $0.10
Q1'21
Beat
by $0.15
Q4'20
Missed
by $0.08
The last earnings report on November 02 showed earnings per share of $1.34, beating the estimate of $1.08. With 27.20M shares outstanding, the current market capitalization sits at 300.51B.
A.I.dvisor found
Pfizer Dividends
PFE is expected to pay dividends on March 04, 2022
Pfizer PFE Stock Dividends
A dividend of $0.40 per share will be paid with a record date of March 04, 2022, and an ex-dividend date of January 27, 2022. The last dividend of $0.39 was paid on December 06. The ex-dividend date is usually set several business days before the record date. If a stock is purchased on its ex-dividend date or after, the next dividend payment will not be received. Instead, the dividends are repossessed by to the seller. If the stocks are purchased before the ex-dividend date, the buyer will receive the dividends.
A.I.dvisor
published General Information

General Information

Profile
Fundamentals
Details
Industry Pharmaceuticals Major
Address 235 East 42nd Street, New York, NY, 10017
Phone +1 212 733-2323
Employees 78500
Web https://www.pfizer.com
PFE

Select Stock attributes to show

Capitalization 301B
P/E Ratio 15.55
Risk (Beta) 0.69
Dividend Yield 0.03
Total Cash 21.7B
Total Cash/Share 3.87
Total Debt 37.7B
Total Debt/Equity 47.59
Projected Growth (PEG Ratio) 1.27
Revenue/Share (as % of the share price) 12%
Revenue 55.5B
ROE N/A
Book Value 70B
P/B Ratio 3.97
Cash Flow N/A
Earnings 2.370
Average Daily Volume YTD N/A
Common Shares Outstanding - Security Level 472M
Current Ratio 1.37
Current Revenue Per Employee 241,745.22
Dividends Per Share - Security 0.39
EBITDA 20.2B
Float N/A
Float - Current N/A
Gross Income Margin 62.86
Revenue To Assets 7.60
Shares Held By Institutions 1.31T
Shares Outstanding - Current N/A
Total Liabilities 99.6B
Total Volume MTD N/A
Value Over
Gain YTD -9.331
Group Domestic Stock Funds
Category Pharmaceuticals
Total Expense Ratio
Min. Initial Investment 0.00 USD
Fund Existence
Turnover
Front Load
Net Assets 0.00 USD
Manager Tenure
Group Domestic Stock Funds
Category Pharmaceuticals
Capitalization 300.51b USD
P/E Ratio 15.5521
Total Cash 21.70b USD
Projected Growth 1.27
Total Debt 37.74b USD
Revenue 55.52b USD
Risk (Beta) 0.69
Dividend Yield 0.03
Total Cash/Share 3.87
Total Debt/Equity 47.59
Revenue/Share 12.00USD as % of share price
Group Domestic Stock Funds
Category Pharmaceuticals
Net Assets 0.00 USD
Fund Existence
Turnover
Capitalization
Yield
Total Expense Ratio
Investment Style
Risk (Beta)
Group Domestic Stock Funds
Category Pharmaceuticals
Market Capitalization 0.00 USD
Volume 0.00 USD